Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ongericimab in heterozygous familial hypercholesterolemia
NCT05325203Phase 3Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Dec 2021
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ongericimab in heterozygous familial hypercholesterolemia (HeFH) (4 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoint: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24. Started Dec 2021; status: completed.
02
Drugs
ongericimab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT05325203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05325203.